Effects of dibekacin, a new aminoglycoside antibiotic, on the rat sciatic nerve-gastrocnemius muscle preparation.
O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1----6)-O-[2,6-diamino-2,3,4,6 -tetradeoxy-alpha-D-erythro-hexopyrano-hexopyranosyl-(1----4 ) ]-2-deoxy-L- streptamine (dibekacin), like other known aminoglycoside antibiotics, possesses a dose-dependent neuromuscular blocking activity in vivo. d-Tubocurarine, at a dose which per se does not influence the contraction of gastrocnemius muscle elicited by sciatic nerve stimulation, significantly potentiates the neuromuscular blockade produced by dibekacin. Neostigmine methylsulfate is unable to reverse the neuromuscular blocking activity of dibekacin, whereas calcium chloride antagonizes the neuromuscular blockade produced by this antibiotic.
D000818:Animals; D002118:Calcium / Q000494:pharmacology; D003982:Dibekacin / Q000494:pharmacology*; D066298:In Vitro Techniques; D007612:Kanamycin / Q000031:analogs & derivatives*; D008297:Male; D009388:Neostigmine / Q000494:pharmacology; D009469:Neuromuscular Junction / Q000187:drug effects*; D051381:Rats; D011919:Rats, Inbred Strains; D012584:Sciatic Nerve / Q000187:drug effects; D014403:Tubocurarine / Q000494:pharmacology
D009388:Neostigmine; D003982:Dibekacin; D007612:Kanamycin; D002118:Calcium; D014403:Tubocurarine